secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001104659-26-032763
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics completes continuance to BC; expects Nevada domestication by March 31
--------------------------------------------------------------------------------

- First step completed March 17: continuance from Alberta to British Columbia under BCBCA.
- Second step expected March 31: domestication to Nevada; shares continue on Nasdaq as ONCY.
- New CUSIP 68237V103 and ISIN US68237V1035 effective April 1; no name change.
- Shareholder rights modified per BCBCA and will change under Nevada law; approved Jan 15, 2026.
- Outstanding common shares unchanged; no impact on trading symbol or exchange listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/0001104659-26-032763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/tm269428d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-032763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer